---
document_datetime: 2024-04-05 15:30:52
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/strimvelis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: strimvelis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.9286465
conversion_datetime: 2025-12-20 16:18:14.672757
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Strimvelis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0039              | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product | 14/12/2023                          | n/a                                         |                                  |           |
| T/0038               | Transfer of Marketing Authorisation                                                                   | 02/06/2023                          | 17/07/2023                                  | SmPC, Labelling and              |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10505 /202211 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence                                                                                                                                                                                                                                    | 06/07/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0037             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                            | 27/03/2023 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0033             | Submission of the final report from study STRIM-001 'Evaluation of referring healthcare providers' and parents'/carers' understanding of specific risks associated with Strimvelis treatment' listed as a category 3 study in the RMP. The RMP version 6.1 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 21/07/2022 | n/a        |                        | This variation discusses the final study results of the post- authorisation study: 'Evaluation of referring Healthcare Providers' and parents'/carers' understanding of specific risks associated with Strimvelis treatment'' (STRIM-001). The study demonstrated that the routine and additional RMMs were effective in informing the HCPs and parents/carers about most of the risks associated with Strimvelis treatment and that the outcome of study STRIM- 001 does not change the current risk-benefit conclusions for Strimvelis. The RMP was updated to reflect the completion of this study. |
| IAIN/0035           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                        | 08/07/2022 | 17/07/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/10505 /202111 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA                                                                                                                                                                                                                                             | 10/06/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | sequence                                                                                                                                                                                       |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                         | 01/12/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10505 /202011 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence | 10/06/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0029              | Renewal of the marketing authorisation.                                                                                                                                                        | 25/02/2021 | 30/04/2021 | SmPC, Annex II, Labelling and PL | Patients treated with Strimvelis gene therapy continued to demonstrate stable efficacy, as evidenced by sustained engraftment of gene modified cells, the maintenance of purine metabolite levels at non-pathological levels, robust immune reconstitution, and significantly fewer severe infections over time. However, a case of Lymphoid T cell leukemia has been reported in a patient with ADA-SCID 4.7 years after treatment with Strimvelis. This first case of a hematological malignancy following treatment with Strimvelis is considered to be due to insertional oncogenesis. Patients should therefore be monitored long term, with at least annual visits for the first 11 years and then at 13- and 15-years post treatment with Strimvelis and include a complete blood count with differential, biochemistry and thyroid stimulating hormone. Despite this event, the Committee agreed that the overall 100 %survival and high rate of intervention free survival |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                 | encompasses significant and clinically relevant benefit for patients with ADA-SCID for whom no suitable matched related stem cell donor is available. Based on the review of data on quality, safety and efficacy, the Committee considered that the benefit-risk balance of Strimvelis in the approved indication remains favourable but considered that this recent safety signal should be closely monitored and, therefore, an additional renewal is recommended to further evaluate the benefit risk balance of this product.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0030/G         | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 16/12/2020 | 30/04/2021 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0028             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                               | 08/07/2020 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10505 /201911 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA                                                                                                                                                                                                                                      | 11/06/2020 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0026   | Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information following the completion of the STRIM-004 study, which is a non- interventional long term follow up of the subjects who received Strimvelis gene therapy. This study included paediatric patients and is listed as a category 3 study in the RMP. The Package Leaflet is updated accordingly. The RMP version 3.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor administrative changes in the PI. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   | 28/05/2020   | n/a        |             | This variation provides the final results of the STRIM-004 study, the long-term follow up of subjects who received Strimvelis gene therapy in four studies previously assessed in the MAA. The study contributes an additional 5 years follow-up data in 16 patients previously treated with Strimvelis. Overall survival remains at 100%. Subjects treated with Strimvelis gene therapy continued to demonstrate stable efficacy. The overall safety profile for Strimvelis is in line with that expected in an ADA-SCID population which has undergone busulfan conditioning and is undergoing immune reconstitution. No new safety findings have been identified. As a result of this variation, the frequency of smooth muscle antibody (ASMA) positive AEs has been amended from Common to Very common and updated information based on results from LTFU study has been included.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024   | Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information following the completion of the STRIM-004 study, which is a non- interventional long term follow up of the subjects who received Strimvelis gene therapy. This study included paediatric patients and is listed as a category 3 study in the RMP. The Package Leaflet is updated accordingly. The RMP version 3.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to                                                                                                                                                                                                                                                                                                           | 30/04/2020   | 30/04/2021 | SmPC and PL | This variation provides the final results of the STRIM-004 study, the long-term follow up of subjects who received Strimvelis gene therapy in four studies previously assessed in the MAA. The study contributes an additional 5 years follow-up data in 16 patients previously treated with Strimvelis. Overall survival remains at 100%. Subjects treated with Strimvelis gene therapy continued to demonstrate stable efficacy and overall survival remains at 100%. The overall safety profile for Strimvelis is in line with that expected in an ADA-SCID population which has                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | introduce minor administrative changes in the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                    |            |     | undergone busulfan conditioning and is undergoing immune reconstitution. No new safety findings have been identified. As a result of this variation, the frequency of smooth muscle antibody (ASMA) positive adverse event has been amended from Common to Very common and updated information based on results from the long-term follow up study has been included.                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 17/04/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0023   | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                | 20/12/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0022   | Submission of an updated RMP version 2.0 in order to introduce changes to the design of the post- authorisation study STRIM-002, from a prospective to a retrospective study. Following additional minor changes to the RMP are also included: Update of the RMP in line with EMA Rev.2.0.1 template; update of the RMP to make the                                                                                                                    | 17/10/2019 | n/a | Through this variation application, the MAH is proposing the revise the design of the study STRIM-002 from prospective to a retrospective analysis of samples previously collected from Strimvelis-treated patients. This proposal to change the retroviral insertion sites analysis is considered acceptable, as the quality of the data obtained should be similar by using a retrospective analysis |

<div style=\"page-break-after: always\"></div>

|                     | necessary amendments to the name of the MAH following the MAH transfer; update of the data in the RMP in line with the updated data lock point; update of timelines for the STRIM-001 study. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |     | instead of a prospective one, assuming that enough stored samples are suitable for testing. In addition, as the MAH states, with the retrospective analysis the data will be available in a short time from now, as compared to the prospective study, which will allow earlier conclusions on the suitability of the SLiM-PCR method for the RIS analysis. Following additional minor changes to the updated RMP are also included: Update of the RMP in line with EMA Rev.2.0.1 template; update of the RMP to make the necessary amendments to the name of the MAH following the MAH transfer; update of the data in the RMP in line with the updated data lock point; update of timelines for the STRIM- 001 study.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/08/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0020/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                      | 31/07/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10505 /201811 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence                                                                                                                                                                                                                                                                                                | 14/06/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0019             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                        | 29/03/2019   | n/a        |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| II/0016             | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                               | 31/01/2019   | n/a        |                        |                                   |
| PSUSA/10505 /201805 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence                                                                                                                                                                                                             | 17/01/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0017             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                               | 09/01/2019   | n/a        |                        |                                   |
| T/0014              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                        | 27/07/2018   | 23/08/2018 | SmPC, Labelling and PL |                                   |
| IA/0013/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 15/06/2018   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10505 /201711 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence               | 14/06/2018 | n/a | PRAC Recommendation - maintenance |
| IB/0012             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                      | 22/05/2018 | n/a |                                   |
| IB/0010             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 01/02/2018 | n/a |                                   |
| PSUSA/10505 /201705 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence               | 11/01/2018 | n/a | PRAC Recommendation - maintenance |
| IB/0009             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                       | 04/12/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0007             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                              | 02/08/2017   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                              | 20/07/2017   | 30/07/2018 | SmPC, Annex II and PL | To introduce changes in section 4.3 and 4.4 of the product information following changes in the analytical control of bone marrow samples of patients to allow prospective patients who have previously tested positive for hepatitis C can be treated with Strimvelis, provided they demonstrate absence of ongoing infection using a nucleic acid test with a limit of quantification of ï‚£ 15 international units/ml. |
| PSUSA/10505 /201611 | Periodic Safety Update EU Single assessment - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence                                                                                                                                                                                                                   | 09/06/2017   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0005             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                              | 28/03/2017   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0003/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 30/01/2017   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0001/G | This was an application for a group of variations. B.I.b.1 z) To change the acceptance criteria for the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/10/2016 | n/a |

<div style=\"page-break-after: always\"></div>

|         | transduction efficiency test for the drug substance from \"Transduction detected\" to \" â‰¥ 29%\". B.I.b.2 d) To replace the method for the measurement of transduction efficiency of the drug substance with an improved transduction efficiency method (the qPCR method). B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a AS   |            |     | biological   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------|
| IB/0002 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 06/09/2016 | n/a |              |